Terumo India Introduces TREO Abdominal Stent-Graft System

This new device addresses a growing need for effective treatments for abdominal aortic aneurysms.

Terumo India, the subsidiary of Terumo Corporation, has unveiled the TREO Abdominal Stent-Graft System, an advanced tool designed to improve Endovascular Aneurysm Repair (EVAR) procedures. 

This new device addresses a growing need for effective treatments for abdominal aortic aneurysms.

The TREO Stent-Graft System is specifically developed to treat infrarenal abdominal aortic aneurysms in patients with compatible anatomies. It is noted for being the only EVAR graft with both suprarenal and infrarenal active fixation capabilities.

The system features a three-piece design with in situ limb adjustability, allowing it to be customized for various patient anatomies. It includes advanced proximal sealing technology aimed at improving stability and reducing the risk of leaks. 

The device also incorporates superior lock stent technology, which enhances fixation and decreases the likelihood of migration. The flexible design allows it to adapt to challenging and angulated anatomy, ensuring improved treatment flexibility and long-term performance.

Recent clinical studies highlight the benefits of the TREO system, showing lower rates of sac shrinkage and reduced need for re-interventions. This suggests that the device could lead to better patient outcomes and fewer follow-up procedures.

Addressing Growing Needs in India

Shishir Agarwal, president and managing director of Terumo India, said, “In India, the prevalence of abdominal aortic aneurysms is rising, with an estimated 1 in 10,000 people affected annually, underscoring the significant need for advanced treatment options.” 

Agarwal’s statement emphasizes the increasing demand for effective aneurysm repair solutions in the country.

The introduction of the TREO Stent-Graft System aligns with the ongoing efforts to enhance healthcare technology in India. By offering a device designed to tackle complex anatomical challenges, Terumo India aims to improve the effectiveness and reliability of endovascular treatments for abdominal aortic aneurysms.

The TREO system’s design allows for precise adaptation to individual patient needs, which could potentially address the limitations of previous devices. 

Earlier, Terumo India introduced the Ultimaster Nagomi, a new-generation drug-eluting stent for treating coronary artery disease. The Ultimaster Nagomi adapts to various artery sizes, allowing for a personalized approach to coronary interventions. Its design facilitates smooth navigation through complex arteries, addressing a broad spectrum of patient needs in coronary care.